Therapeutic Effect of Cytotoxic T Lymphocyte Antigen 4/Immunoglobulin on a Murine Model of Primary Biliary Cirrhosis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Collectively, the data in both humans and murine models of human primary biliary cirrhosis (PBC) suggest that activated T cells, particularly CD8 T cells, play a critical role in biliary cell destruction. Under physiological conditions, T-cell activation involves two critical signals that involve the major histocompatibility complex and a set of costimulatory molecules, which include a receptor on T cells termed cytotoxic T lymphocyte antigen 4 (CTLA-4). Germane to the studies reported herein, signaling by CTLA-4 has the potential to modulate costimulation and induce inhibitory signals. In this study, we have taken advantage of our well-defined murine model of PBC, in which mice are immunized with 2-octynoic acid coupled to bovine serum albumin (2OA-BSA), leading to the production of high-titer antimitochondrial autoantibodies (AMAs) and portal cellular infiltrates. To investigate the potential of CTLA-4-Ig (immunoglobulin) as an immunotherapeutic agent, we treated mice both before and after induction of autoimmune cholangitis. First, we demonstrate that CTLA-4-Ig treatment, begun 1 day before 2OA-BSA immunization, completely inhibits the manifestations of cholangitis, including AMA production, intrahepatic T-cell infiltrates, and bile duct damage. However, and more critically, treatment with CTLA-4-Ig, initiated after the development of autoimmune cholangitis in previously immunized mice, also resulted in significant therapeutic benefit, including reduced intrahepatic T-cell infiltrates and biliary cell damage, although AMA levels were not altered. Conclusion: These data suggest that an optimized regimen with CTLA-4-Ig has the potential to serve as an investigative therapeutic tool in patients with PBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · cited 1×
“This results in decreased cytokine production, inhibition of cell-cycle progression, downmodulation of T-cell receptor (TCR) signaling, and decreased activation of B cells and macrophages.(21-26) These properties of CTLA-4 prompted us to explore the potential of CTLA-4-based therapy for PBC utilizing our murine model…”
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“This results in decreased cytokine production, inhibition of cell-cycle progression, downmodulation of T-cell receptor (TCR) signaling, and decreased activation of B cells and macrophages.(21-26) These properties of CTLA-4 prompted us to explore the potential of CTLA-4-based therapy for PBC utilizing our murine model…”
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · cited 1×
“This results in decreased cytokine production, inhibition of cell-cycle progression, downmodulation of T-cell receptor (TCR) signaling, and decreased activation of B cells and macrophages.(21-26) These properties of CTLA-4 prompted us to explore the potential of CTLA-4-based therapy for PBC utilizing our murine model…”
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Kita, H., Matsumura, S., He, X.-S., Ansari, A. A., Lian, Z.-X., Van de Water, J., Coppel, R. L., Kaplan, M. M., & Gershwin, M. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214698 · Cited by 222
Self-citation
Cited by
Mieli-Vergani, G., Vergani, D., Czaja, A. J., Manns, M. P., Krawitt, E. L., Vierling, J. M., Lohse, A. W., & Montano-Loza, A. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.17 · Cited by 425
The ascending pathophysiology of cholestatic liver disease
Jansen, P. L. M., Ghallab, A., Vartak, N., Reif, R., Schaap, F. G., Hampe, J., & Hengstler, J. G. (2017) · Hepatology · doi:10.1002/hep.28965 · Cited by 301
“Reduction of bile viscosity; increasing bicarbonate production UDCA 24-norUDCA Tauro-UDCA TGR5 agonists Urso Falk, Ursochol NorUrso Falk(85) TUDCA(86) INT 777(87) Recommended and approved for PBC PSC, 01755507 PBC, 01829698, 01857284 Not yet in trial 2 3 Increase phospholipid secretion PPARa agonists Fenofibrate(88) B…”
The autoimmune basis of alopecia areata: A comprehensive review
Islam, N., Leung, P. S. C., Huntley, A. C., & Eric Gershwin, M. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.10.014 · Cited by 269
Self-citationThe diagnosis of primary biliary cirrhosis
Bowlus, C. L., & Gershwin, M. E. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.041 · Cited by 162
Environmental Basis of Autoimmunity
Floreani, A., Leung, P. S. C., & Gershwin, M. E. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8493-8 · Cited by 122
Self-citationNovel therapeutic targets in primary biliary cirrhosis
Dyson, J. K., Hirschfield, G. M., Adams, D. H., Beuers, U., Mann, D. A., Lindor, K. D., & Jones, D. E. J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.12 · Cited by 120
Jin, C., Jiang, P., Zhang, Z., Han, Y., Wen, X., Zheng, L., Kuang, W., Lian, J., Yu, G., Qian, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53104-9 · Cited by 56
A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis
Chen, R., Huang, B., Lian, M., Wei, Y., Miao, Q., Liang, J., Ou, Y., Liang, X., Zhang, H., Li, Y., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.016 · Cited by 39
Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends
Gao, L., Wang, L., Woo, E., He, X., Yang, G., Bowlus, C., Leung, P. S. C., & Gershwin, M. E. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08772-7 · Cited by 39
Self-citation
Metadata
- Authors
- Dhirapong, A., Yang, G.-X., Nadler, S., Zhang, W., Tsuneyama, K., Leung, P., Knechtle, S., Ansari, A. A., Coppel, R. L., Liu, F.-T., He, X.-S., & Gershwin, E. M.
- Venue
- Hepatology
- Published
- 2013-02
- Volume
- 57
- Issue
- 2
- Pages
- 708-715
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2028940135
- Cited by
- 96
- References
- 5
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.